Your study on active pharmacovigilance is commendable, but critical issues persist. The small sample size, lack of multivariable analysis, and unverified claims of underreporting weaken the findings. Discrepancies in ADR risk calculations and inadequate methodological transparency further compromise reliability. Addressing these concerns is crucial for scientific rigor.